This Biotech Disruptor Has Gone From Penny Stock To Big Mover On The Nasdaq

Earlier this year, the biotech company featured in today’s article was a penny stock. But after uplisting to the Nasdaq, the author of today’s article notes that “it has been making big moves in the market and moving some of Wall Street’s top analysts to set initial targets over $20 right now.” For more on how this company’s approach to personalized medicine could disrupt the industry and make the stock’s recent big moves just the tip of the iceberg, CLICK HERE.